| Title |
Diagnosis, management, and monitoring of interleukin-1 mediated diseases in Central and Eastern Europe: real-world data |
| Authors |
Jelusic, Marija ; Sestan, Mario ; Toplak, Natasa ; Tamas, Constantin ; Vojinovic, Jelena ; Zuber, Zbigniew ; Wolska-Kusnierz, Beata ; Sparchez, Mihaela ; Jesenak, Milos ; Rusonienė, Skirmantė ; Stanevica, Valda ; Dolezalova, Pavla ; Harel, Liora ; Uziel, Yosef ; Gattorno, Marco |
| DOI |
10.1186/s12969-025-01105-3 |
| Full Text |
|
| Is Part of |
Pediatric rheumatology.. London : BioMed Central Ltd. 2025, vol. 23, iss. 1, art. no. 56, p. [1-8].. eISSN 1546-0096 |
| Keywords [eng] |
autoinflammatory diseases ; diagnosis ; Interleukin-1 mediated diseases ; monitoring ; patient-reported outcomes ; transition ; treatment |
| Abstract [eng] |
Background: Global healthcare disparities, stemming from organizational differences in healthcare systems, lead to variable availability and funding, resulting in a gap between recommended and implemented practices for interleukin (IL)-1-mediated autoinflammatory diseases. We aimed to assess diagnostic, treatment and follow-up options for these diseases in Central and Eastern European countries, comparing them with the 2021 recommendations of the European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR). Methods: In 2023, a structured collaborative effort was organized with representatives from 10 Central and Eastern European countries to address autoinflammatory diseases. The discussion focused on potential strategies to achieve the goals mentioned above. Results: Almost all the participating countries have specialized centers for the diagnosis and treatment of autoinflammatory diseases and the care is provided either by rheumatologists and/or clinical immunologists. Genetic testing is available in all countries, but there is variation in the types of tests offered. Massive parallel sequencing panels for autoinflammatory diseases are available in all countries, with waiting periods for results ranging from 3 to 6 months in most cases. The availability of disease-specific laboratory assessments, such as S100 proteins, is limited. IL-1 inhibitors are available in all countries, but there are differences in practices regarding the licensing and reimbursement of anakinra and canakinumab based on specific indications or diagnoses. The age at which the transition process begins varies, but in most countries, it typically starts around the age of 18 or beyond and in majority of the participating countries there is no structured transition program. Conclusions: Adherence to the 2021 EULAR/ACR recommendations for IL-1-mediated autoinflammatory diseases is achievable in Central and Eastern European countries. Determining the prevalence and incidence of these diseases in this region remains a persistent challenge for future research efforts, with the overarching goal of identifying new patients with autoinflammatory diseases. |
| Published |
London : BioMed Central Ltd |
| Type |
Journal article |
| Language |
English |
| Publication date |
2025 |
| CC license |
|
